Literature DB >> 11558810

Isopropyl unoprostone increases the activities of matrix metalloproteinases in cultured monkey ciliary muscle cells.

K Kashiwagi1, M Jin, M Suzuki, Y Tanaka, Y Iizuka, S Tsukahara.   

Abstract

PURPOSE: The mechanism by which the prostaglandin F2alpha-related antiglaucoma compound isopropyl unoprostone (referred to as unoprostone) reduces intraocular pressure is largely unknown. Another prostaglandin F2alpha-related compound, latanoprost, influences the activities of matrix metalloproteinases in ciliary muscle. Unoprostone ophthalmic solution is metabolized to oxidized metabolites, mainly M1 and M2, in the eye. The aim of this study was to investigate whether intraocular metabolites of unoprostone, M1 and M2, change the metalloproteinase activity in cultured monkey ciliary muscle cells.
MATERIALS AND METHODS: Monkey ciliary muscle cells and trabecular meshwork cells were grown separately to confluence in monolayer cell cultures. M1 (10 nM, 100 nM, or 1 microM), M2 (10 nM, 100 nM, or 1 microM), 100 nM prostaglandin F2alpha, or vehicle solutions were added to each culture medium for 48 hours. The media were then assayed to measure metalloproteinase activities quantitatively by means of substrate zymography.
RESULTS: Compared with the vehicle controls, M1, M2, and prostaglandin F2alpha significantly increased the metalloproteinase-2 activity in cultured ciliary muscle cells in a dose-dependent manner, but did not affect the metalloproteinase-2 activity in cultured trabecular meshwork cells. All experimented prostaglandins slightly increased metalloproteinase-9 activity in ciliary muscle cells, although these changes were not significant.
CONCLUSIONS: The current results show that unoprostone influences the metabolism of the extracellular matrix in the ciliary muscle and that remodeling of the extracellular matrix in the ciliary muscle may be a possible mechanism by which unoprostone ophthalmic solution reduces intraocular pressure.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11558810     DOI: 10.1097/00061198-200108000-00005

Source DB:  PubMed          Journal:  J Glaucoma        ISSN: 1057-0829            Impact factor:   2.503


  3 in total

1.  Additional reduction in intraocular pressure achieved with latanoprost in normal-tension glaucoma patients previously treated with unoprostone.

Authors:  Miho Enoki; Jun Saito; Makiko Hara; Tetsuya Uchida; Takeshi Sagara; Teruo Nishida
Journal:  Jpn J Ophthalmol       Date:  2006 Jul-Aug       Impact factor: 2.447

Review 2.  An evidence-based review of unoprostone isopropyl ophthalmic solution 0.15% for glaucoma: place in therapy.

Authors:  Derrick S Fung; Jess T Whitson
Journal:  Clin Ophthalmol       Date:  2014-03-10

3.  In Vitro Screening and Transfection Concentration Optimization of Cynomolgus Monkey IκBα-siRNA.

Authors:  Zhaoxing Ou; Rui Zeng; Yifan Lin; Si Zhang; Mohammad Alzogool; Peng Zeng; Yuqing Lan
Journal:  J Ophthalmol       Date:  2020-04-15       Impact factor: 1.909

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.